Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
1601
mi
from 02139
Houston, TX
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
1601
mi
from 02139
Houston, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Consultants of San Antonio
1751
mi
from 02139
San Antonio, TX
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Consultants of San Antonio
1751
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Texas Digestive Disease Consultants - Southlake
1556
mi
from 02139
Southlake, TX
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Texas Digestive Disease Consultants - Southlake
1556
mi
from 02139
Southlake, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Digestive Health Specialists of Tyler
1491
mi
from 02139
Tyler, TX
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Digestive Health Specialists of Tyler
1491
mi
from 02139
Tyler, TX
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Ericksen Research And Development
2091
mi
from 02139
Clinton, UT
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Ericksen Research And Development
2091
mi
from 02139
Clinton, UT
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
University of Utah School of Medicine; Psychiatry
2088
mi
from 02139
Salt Lake City, UT
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
University of Utah School of Medicine; Psychiatry
2088
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health Systems; Gastroenterology and Hepatology
491
mi
from 02139
Charlottesville, VA
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health Systems; Gastroenterology and Hepatology
491
mi
from 02139
Charlottesville, VA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Digestive and Liver Disease Specialists
467
mi
from 02139
Norfolk, VA
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Digestive and Liver Disease Specialists
467
mi
from 02139
Norfolk, VA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
McGuire Research Institute; Gastroenterology
472
mi
from 02139
Richmond, VA
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
McGuire Research Institute; Gastroenterology
472
mi
from 02139
Richmond, VA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Northwest Gastroenterology Associates
2477
mi
from 02139
Bellevue, WA
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Northwest Gastroenterology Associates
2477
mi
from 02139
Bellevue, WA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center; Swedish Gastroenterology
2482
mi
from 02139
Seattle, WA
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center; Swedish Gastroenterology
2482
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
University of Washington / Harborview Medical Center; University of Washington
2482
mi
from 02139
Seattle, WA
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
University of Washington / Harborview Medical Center; University of Washington
2482
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
The Vancouver Clinic
2524
mi
from 02139
Vancouver, WA
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
The Vancouver Clinic
2524
mi
from 02139
Vancouver, WA
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
853
mi
from 02139
Milwaukee, WI
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
853
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Hospital Universitário Professor Edgard Santos - Universidade Federal da Bahia
4347
mi
from 02139
Salvador,
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Hospital Universitário Professor Edgard Santos - Universidade Federal da Bahia
4347
mi
from 02139
Salvador,
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
West Central Gastroenterology d/b/a Gastro Florida
1191
mi
from 02139
Clearwater, FL
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
West Central Gastroenterology d/b/a Gastro Florida
1191
mi
from 02139
Clearwater, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Peak Gastroenterology Associates; Gastroenterology
1772
mi
from 02139
Colorado Springs, CO
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Peak Gastroenterology Associates; Gastroenterology
1772
mi
from 02139
Colorado Springs, CO
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Innovative Medical Research of South Florida Inc.
1243
mi
from 02139
Aventura, FL
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Innovative Medical Research of South Florida Inc.
1243
mi
from 02139
Aventura, FL
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
VA Medical Center
856
mi
from 02139
Milwaukee, MI
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
VA Medical Center
856
mi
from 02139
Milwaukee, MI
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Consult and Research Associates
686
mi
from 02139
Saint Louis, MI
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Consult and Research Associates
686
mi
from 02139
Saint Louis, MI
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Concorde Medical Group
185
mi
from 02139
New York, NY
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Concorde Medical Group
185
mi
from 02139
New York, NY
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Central Sooner Research
1495
mi
from 02139
Norman, OK
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Central Sooner Research
1495
mi
from 02139
Norman, OK
Click here to add this to my saved trials
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated:  12/31/1969
Gastro One
1123
mi
from 02139
Germantown, TN
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Enrolling
Updated: 12/31/1969
Gastro One
1123
mi
from 02139
Germantown, TN
Click here to add this to my saved trials
Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis
Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
1546
mi
from 02139
Dallas, TX
Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis
Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
1546
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Study To Understand Fall Reduction and Vitamin D in You
Vitamin D Supplements to Prevent Falls in Older Adults: A Dose-Response Trial
Status: Enrolling
Updated:  12/31/1969
Prohealth Clinical Research Unit
360
mi
from 02139
Baltimore, MD
Study To Understand Fall Reduction and Vitamin D in You
Vitamin D Supplements to Prevent Falls in Older Adults: A Dose-Response Trial
Status: Enrolling
Updated: 12/31/1969
Prohealth Clinical Research Unit
360
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
Study To Understand Fall Reduction and Vitamin D in You
Vitamin D Supplements to Prevent Falls in Older Adults: A Dose-Response Trial
Status: Enrolling
Updated:  12/31/1969
Comstock Center for Public Health Research and Prevention
392
mi
from 02139
Hagerstown, MD
Study To Understand Fall Reduction and Vitamin D in You
Vitamin D Supplements to Prevent Falls in Older Adults: A Dose-Response Trial
Status: Enrolling
Updated: 12/31/1969
Comstock Center for Public Health Research and Prevention
392
mi
from 02139
Hagerstown, MD
Click here to add this to my saved trials
Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME
Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Osteoporosis Clinical and Research Program
930
mi
from 02139
Madison, WI
Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME
Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Osteoporosis Clinical and Research Program
930
mi
from 02139
Madison, WI
Click here to add this to my saved trials
Heartland Osteoporosis Prevention Study
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
1276
mi
from 02139
Omaha, NE
Heartland Osteoporosis Prevention Study
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
1276
mi
from 02139
Omaha, NE
Click here to add this to my saved trials
Non-operative Management of Pediatric Appendicitis With an Appendicoltih
Non-operative Management of Uncomplicated Appendicitis With an Appendicolth in Children
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
639
mi
from 02139
Columbus, OH
Non-operative Management of Pediatric Appendicitis With an Appendicoltih
Non-operative Management of Uncomplicated Appendicitis With an Appendicolth in Children
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
639
mi
from 02139
Columbus, OH
Click here to add this to my saved trials
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine Medical Center
2576
mi
from 02139
Orange, CA
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine Medical Center
2576
mi
from 02139
Orange, CA
Click here to add this to my saved trials
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Status: Enrolling
Updated:  12/31/1969
Christana Hospital
293
mi
from 02139
Wilmington, DE
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Status: Enrolling
Updated: 12/31/1969
Christana Hospital
293
mi
from 02139
Wilmington, DE
Click here to add this to my saved trials
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Status: Enrolling
Updated:  12/31/1969
WellSpan Health-York Hospital
336
mi
from 02139
York, PA
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department
Status: Enrolling
Updated: 12/31/1969
WellSpan Health-York Hospital
336
mi
from 02139
York, PA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Arizona Clinical Research Center
2272
mi
from 02139
Tucson, AZ
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Arizona Clinical Research Center
2272
mi
from 02139
Tucson, AZ
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Kansas City Research Institute
1246
mi
from 02139
Kansas City, MO
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Kansas City Research Institute
1246
mi
from 02139
Kansas City, MO
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Cancer Research Centers
1545
mi
from 02139
Dallas, TX
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Cancer Research Centers
1545
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
2692
mi
from 02139
San Francisco, CA
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
2692
mi
from 02139
San Francisco, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Princess Margaret Hospital
427
mi
from 02139
Toronto,
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Princess Margaret Hospital
427
mi
from 02139
Toronto,
Click here to add this to my saved trials
Tesamorelin Effects on Liver Fat and Histology in HIV
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health
390
mi
from 02139
Bethesda, MD
Tesamorelin Effects on Liver Fat and Histology in HIV
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Tesamorelin Effects on Liver Fat and Histology in HIV
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Tesamorelin Effects on Liver Fat and Histology in HIV
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1
mi
from 02139
Boston, MA
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
Using Electrical Bioimpedance Assessments to Estimate Perioperative Total Body Water and Postoperative Fluid Need
The Use of Multifrequency Bioimpedance Assessments as an Estimate of Perioperative Total Body Volume and Postoperative Fluid Resuscitation
Status: Enrolling
Updated:  12/31/1969
Naval Medical Center - Portsmouth
471
mi
from 02139
Portsmouth, VA
Using Electrical Bioimpedance Assessments to Estimate Perioperative Total Body Water and Postoperative Fluid Need
The Use of Multifrequency Bioimpedance Assessments as an Estimate of Perioperative Total Body Volume and Postoperative Fluid Resuscitation
Status: Enrolling
Updated: 12/31/1969
Naval Medical Center - Portsmouth
471
mi
from 02139
Portsmouth, VA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
180
mi
from 02139
New York, NY
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
180
mi
from 02139
New York, NY
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2550
mi
from 02139
La Jolla, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2550
mi
from 02139
La Jolla, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2580
mi
from 02139
Pasadena, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2580
mi
from 02139
Pasadena, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2690
mi
from 02139
San Francisco, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2690
mi
from 02139
San Francisco, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1755
mi
from 02139
Aurora, CO
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1755
mi
from 02139
Aurora, CO
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
391
mi
from 02139
Washington,
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
391
mi
from 02139
Washington,
Click here to add this to my saved trials